mm

About Jason Novak

Jason has been a consistent contributor to VectorVest and has a blended interest in technology and finance, which he has written about for over a decade. When he's not demystifying complex financial topics or sharing a quick analysis of hot stocks on a given day, you may find him on the golf course or exploring all that Northern California has to offer.
27 06, 2024

Micron Tech Tumbles 6% on Less Than Fantastic Forecast: 3 Reasons It’s STILL Time to Buy MU

By |2024-06-27T17:45:34+00:00June 27th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Micron Tech (MU) reported its fiscal Q3 earnings results alongside a forecast for the final quarter of the fiscal year, and shares slid 6% as investors were expecting more. Revenue came in at $6.81 billion for the quarter, which was a whopping 81% improvement year over year. Analysts were expecting $6.61 billion.  Meanwhile, earnings [...]

26 06, 2024

FedEx Cost Cuts and Upbeat Outlook Send Shares 14% Higher: 3 Other Reasons to BUY FDX

By |2024-06-26T18:15:27+00:00June 26th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , |

It had been a tough past few months for FedEX (FDX) investors, who watched their positions plummet 14%. But shares have recovered all that and more today after the delivery company released positive 4th quarter results for fiscal 2024. Earnings came in at $5.94 per share, which was ahead of the analyst expectation of [...]

25 06, 2024

Analysts are Bullish on IBM, But is it Actually Time to Buy This Stock? 3 Things to Consider First

By |2024-06-25T16:26:40+00:00June 25th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Goldman Sachs analyst James Schneider helped send shares of International Business Machines (IBM) higher Monday with a bullish outlook on the company for the road ahead. He set a price target at $200 and says it’s time to buy this stock, which currently sits at $173. Schneider is bullish on the IT services segment [...]

24 06, 2024

Should You Buy Chipotle (CMG) Ahead of the 50-for-1 Stock Split? 3 Things to Consider

By |2024-06-24T17:43:31+00:00June 24th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

The 50-for-1 stock split of Chipotle Mexican Grill (CMG) is scheduled to go live tomorrow (Tuesday, 6/25) after the market closes. As one of the largest stock splits in the history of the NYSE, all eyes are on the stock as the clock ticks down. Those who are new to the concept of stock [...]

23 06, 2024

Top 10 Monthly Dividend Stocks to Hold Forever

By |2024-07-09T13:19:13+00:00June 23rd, 2024|Categories: Stock Market|Tags: , |

Investing in monthly dividend stocks is a great way to earn consistent income to cover ongoing expenses. Or, you could be trying to invest for early retirement hoping to harness the compounding returns dividend stocks have to offer. Whatever the case, you’ve come to the right place. We’re going to unveil the top 10 monthly [...]

22 06, 2024

Pros and Cons of Dividend Stocks

By |2024-06-11T01:40:37+00:00June 22nd, 2024|Categories: Stock Market|Tags: , |

Dividend stocks are one of the top stock investment strategies as they can provide supplemental income for present-day expenses OR be used to build towards long-term wealth goals through a reinvestment strategy.  No matter your goals with investing in dividend stocks, you’re typically going to enjoy much less volatility. We consider blue chip stocks with [...]

21 06, 2024

Sarepta Shoots up 36% on New Drug Breakthrough for DMD: 2 Reasons to Consider Buying SRPT

By |2024-06-21T17:20:17+00:00June 21st, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , |

Sarepta Therapeutics (SRPT) announced late Thursday it had gained FDA approval for its treatment designed to target a rare genetic disease known as Duchenne muscular dystrophy (DMD). This condition causes progressive weakness, predominantly in boys, and is caused by a lack of key protein dystrophin. It has no known cure at this time. The [...]

20 06, 2024

Accenture Jumps 7% on Upbeat Forecast Despite Earnings Miss: Does AI Growth Make ACN a BUY?

By |2024-06-20T18:04:51+00:00June 20th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Accenture (ACN) delivered fiscal Q3 results Thursday morning right before the market opened, and despite a miss on the top and bottom lines, the company’s forecast for the road ahead was enough to send shares nearly 7% higher. Revenue for the third quarter was disappointing at just $16.47 billion, narrowly below the $16.53 billion [...]

19 06, 2024

Dell Was Down After Disappointing Earnings, But the Road to Recovery is Underway: Time to Buy?

By |2024-06-19T17:32:29+00:00June 19th, 2024|Categories: Feature: Stock Market Investing, Featured: News, Stock Market News|Tags: , , , , , , , , |

Just last month Dell Technologies (DELL) reported first-quarter earnings that fell short of Wall Street’s expectations, taking the stock down from its all-time high of $179/share. It fell more than 30% in just a few days, eroding market cap and scaring investors out of their positions.  The issue was that despite AI growth fueling [...]

19 06, 2024

How Many Dividend Stocks Should I Own? Tips on Building a Dividend Portfolio

By |2024-07-30T14:18:32+00:00June 19th, 2024|Categories: Stock Market|Tags: , , , |

Dividend stocks are a great way to achieve long-term capital growth or short-term income depending on your goals, which is why learning how to build a dividend portfolio is one of the best stock investment strategies. But how many dividend stocks should I own? Why is diversification so important? What are some diversified dividend portfolio [...]

Go to Top